Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Fraud Cases: Beat Goes On As Whistleblowers Pursue Lesser Allegations

Executive Summary

“There are enough layoffs out there that there is this walking group of disaffected people who are continuing to file qui tams, whether those are valid or not,” Boston Assistant U.S. Attorney Susan Winkler says. A Pfizer attorney suggests proactive steps to protect corporate leaders from prosecution.

You may also be interested in...



Pharma Under The Gun: FDA And DoJ Use Tough Tactics In Investigations

Former government attorneys offer advice on how companies can respond to government search warrants and fake identities; current prosecutors discuss the tools they use and the kinds of cases they are pursuing.

The Era Of Billion Dollar Pharma Settlements

Abbott Laboratories is the third pharmaceutical company to reach a settlement with the Department of Justice in excess of $1 billion. A look at the deals struck since Eli Lilly began the billion dollar club in 2009 shows the activities the government is investigating and the level of liability that companies face.

User Fee Legislation Revs Through Senate Mark-up, But House Bill Goes Back Into The Shop

Senate health committee defers action on several potentially contentious issues, with members hoping to resolve differences over FDA’s authorities on imports, shortages, foreign data and track-and-trace before the bill goes to the floor, possibly in May. Meanwhile, the House postpones its mark-up in an effort to craft a more bipartisan bill, and now will try to push the user fee package to the floor during an upcoming four-day marathon session.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel